Abstract
A series of 19 isonicotinic acid hydrazide derivatives has been synthesized and evaluated for their in vitro antitubercular activity against Mycobacterium tuberculosis H37Rv using alamar blue susceptibility test. The synthesized compounds inhibit Mycobacterium tuberculosis H37Rv strain with minimum inhibitory concentration ranging from (0.00014-0.01174 mM). Among all synthesized compounds seven derivatives 2a, 2b, 2e, 2h, 2l, 2m and 2q were more potent than isoniazid and the compound 2q emerged as the most potent derivative, being more effective than isoniazid with an (MIC 0.00023 mM) in vitro. The results demonstrated the potential and importance of developing new isoniazid derivatives against Mycobacterium infections.
Keywords: Isonicotinoyl hydrazones, Mycobacterium tuberculosis H37Rv, Antitubercular activity, IR, 1H NMR, C-NMR, hydrazide Derivatives, Antitubercular Agents, Tuberculosis, Mycobacterium tuberculi, amikacin, capreomycin, HIV-1 seropositive, chemotherapy, chromosomal mutation, isonicotinoyl hydrazone
Letters in Drug Design & Discovery
Title: Synthesis, Characterization of (E)-N'-(substituted-benzylidene)isonicotinohydrazide Derivatives as Potent Antitubercular Agents
Volume: 8 Issue: 6
Author(s): Manav Malhotra, Rajiv Sharma, Vikramdeep Monga, Aakash Deep, Kapendra Sahu and Abdul Samad
Affiliation:
Keywords: Isonicotinoyl hydrazones, Mycobacterium tuberculosis H37Rv, Antitubercular activity, IR, 1H NMR, C-NMR, hydrazide Derivatives, Antitubercular Agents, Tuberculosis, Mycobacterium tuberculi, amikacin, capreomycin, HIV-1 seropositive, chemotherapy, chromosomal mutation, isonicotinoyl hydrazone
Abstract: A series of 19 isonicotinic acid hydrazide derivatives has been synthesized and evaluated for their in vitro antitubercular activity against Mycobacterium tuberculosis H37Rv using alamar blue susceptibility test. The synthesized compounds inhibit Mycobacterium tuberculosis H37Rv strain with minimum inhibitory concentration ranging from (0.00014-0.01174 mM). Among all synthesized compounds seven derivatives 2a, 2b, 2e, 2h, 2l, 2m and 2q were more potent than isoniazid and the compound 2q emerged as the most potent derivative, being more effective than isoniazid with an (MIC 0.00023 mM) in vitro. The results demonstrated the potential and importance of developing new isoniazid derivatives against Mycobacterium infections.
Export Options
About this article
Cite this article as:
Malhotra Manav, Sharma Rajiv, Monga Vikramdeep, Deep Aakash, Sahu Kapendra and Samad Abdul, Synthesis, Characterization of (E)-N'-(substituted-benzylidene)isonicotinohydrazide Derivatives as Potent Antitubercular Agents, Letters in Drug Design & Discovery 2011; 8 (6) . https://dx.doi.org/10.2174/157018011795906866
DOI https://dx.doi.org/10.2174/157018011795906866 |
Print ISSN 1570-1808 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-628X |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Anti-Tuberculosis Drug Induced Hepatotoxicity and Genetic Polymorphisms in Drug-metabolizing Genes
Current Pharmacogenomics Lymphadenopathy as a Prodrome for Systemic Lupus Erythematous
Current Rheumatology Reviews New and Old Hot Drug Targets in Tuberculosis
Current Medicinal Chemistry A New Battlefield Towards Global Health in 21<sup>st</sup> Century: Clinical Research Networks
Applied Clinical Research, Clinical Trials and Regulatory Affairs Medicinal Plants for the Treatment of Asthma: A Traditional Persian Medicine Perspective
Current Pharmaceutical Design 2 Receptor Specific Ligand Conjugated Nanocarriers: An Effective Strategy for Targeted Therapy of Tuberculosis
Current Drug Delivery The Use of Proteomics to Study Infectious Diseases
Infectious Disorders - Drug Targets Psoriasis in Children: A Review
Current Pediatric Reviews Novel Dibenzothiepins with Antibiofilm Activity Demonstrated by Microbiological Assays and Molecular Modeling
Current Organic Chemistry Post-Translational Protein Modifications of Rare and Unconventional Types: Implications in Functions and Diseases
Current Medicinal Chemistry Diagnostic, Prognostic and Therapeutic Potential of Heat Shock Proteins in Schistosomiasis and Bladder Cancer: A Review
Letters in Drug Design & Discovery Volatilome Metabolomics and Databases, Recent Advances and Needs
Current Metabolomics Bacteriophage and Peptidoglycan Degrading Enzymes with Antimicrobial Applications
Recent Patents on Biotechnology Glycan Phosphorylases in Multi-Enzyme Synthetic Processes
Protein & Peptide Letters Antimicrobial peptides for the treatment of pulmonary tuberculosis, allies or foes?
Current Pharmaceutical Design HIV-1 Infection In Children: A Clinical and Immunologic Overview
Current HIV Research An Overview on the Potential Antimycobacterial Agents Targeting Serine/Threonine Protein Kinases from Mycobacterium tuberculosis
Current Topics in Medicinal Chemistry Potential Application of Network Descriptions for Understanding Conformational Changes and Protonation States of ABC Transporters
Current Pharmaceutical Design Immunotherapeutic Impact of Toll-like Receptor Agonists in Breast Cancer
Anti-Cancer Agents in Medicinal Chemistry Brucella Carbonic Anhydrases: New Targets for Designing Anti-Infective Agents
Current Pharmaceutical Design